Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
Julie R. Brahmer(Johns Hopkins University), Jon M. Wigginton(Bristol-Myers Squibb (United States)), Kunle Odunsi(University of Chicago), Theresa M. Salay(Johns Hopkins University), Luis H. Camacho(St. Luke's Episcopal Hospital), Omid Hamid(Cedars-Sinai Medical Center), Charles G. Drake(Columbia University Irving Medical Center), Shruti Agrawal(Bristol-Myers Squibb (United States)), Shailender Bhatia(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Wen-Jen Hwu(The University of Texas MD Anderson Cancer Center), Alan J. Korman(Bristol-Myers Squibb (Germany)), S. Goldberg(MacroGenics (United States)), Suzanne L. Topalian(Bloomberg (United States)), John Kauh(Houston Methodist Sugar Land Hospital), Keith D. Eaton(Seattle Cancer Care Alliance), Drew M. Pardoll(Bloomberg (United States)), Laura Q.M. Chow(The University of Texas at Austin), Shuming Chen(Oberlin College), Suresh Alaparthy(Bristol-Myers Squibb (United States)), Patrick Hwu(Moffitt Cancer Center), Renato Martins(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Susan Parker(Bristol-Myers Squibb (United States)), Ashok Gupta, Scott S. Tykodi(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Henry C. Pitot(Mayo Clinic), Joseph F. Grosso(Bristol-Myers Squibb (United States))
Cited by 7,990
Related Papers
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
|New England Journal of Medicine|2012|12.6k
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
|New England Journal of Medicine|2015|9.4k
Nivolumab plus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2013|4.2k